surmount-1 tirzepatide obesity nejm 2022 weight loss percent Weight-Loss Titans: vs. Semaglutide in Tirzepatide for maintenance of bodyweight

Are the units the same

Energy and mood Changes in energy and mood often precede changes on the scale

All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance

Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide activates GLP-1 receptors

Yan Deng, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

GLP-1 receptor agonists have emerged as a major advancement, offering clinically meaningful and sustained weight loss alongside improvements in glycemic control and cardiovascular outcomes